Preliminary data show patients with advanced COVID-19 who received the antiviral drug remdesivir recovered faster than similar patients who received a placebo, federal health officials said Wednesday.
“The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Disease, who announced the results.
Of the more than 1,000 people in the clinical trial internationally, 103 were enrolled in Emory University’s part of the study. The Emory patients were the largest enrollment group in the National Institutes of Health study.
Read this story now for free
To continue reading, sign up for our newsletter and get unlimited access to WABE.org
You can select your preferences for news and local content. We will never share your email address. Learn how your newsletter sign-up will support WABE and Public Media
